Vaxart Announces the Publication of Studies in the Peer-Reviewed Journal Science Translational Medicine That Suggest Mucosal Immunization Could Decrease SARS-CoV-2 Transmission
19 mai 2022 08h30 HE
|
Vaxart, Inc.
A preclinical study in hamsters showed both a decrease in infectious virus and in transmission Phase 1 data measuring cross-reactivity also included in the publication SOUTH SAN FRANCISCO, Calif.,...
Vaxart Provides Business Update and Reports First Quarter 2022 Financial Results
09 mai 2022 17h46 HE
|
Vaxart, Inc.
Data from COVID-19 Phase II study and norovirus Phase IB study are expected in 2022 Ended the 1st Quarter with $157.0 million in cash, cash equivalents and marketable securities SOUTH SAN FRANCISCO,...
Vaxart to Present at World Vaccine Congress Washington 2022 on April 20
14 avr. 2022 08h30 HE
|
Vaxart, Inc.
SOUTH SAN FRANCISCO, Calif., April 14, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, SVP and Chief Scientific Officer, will present at the World Vaccine...
Vaxart Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results
24 févr. 2022 16h05 HE
|
Vaxart, Inc.
Company begins 2022 with multiple active programs with data readouts expected this year Initial data from COVID-19 Phase II study expected in the first half of 2022 and data from several norovirus...
Vaxart’s S-Only COVID-19 Vaccine Candidate Produces Strong-Cross Reactive Mucosal and Systemic Immune Responses in Non-Human Primates
24 févr. 2022 08h30 HE
|
Vaxart, Inc.
Newly published data demonstrates substantial cross-reactivity against multiple variants of COVID-19 S-only candidate is believed to be the first to demonstrate robust neutralizing antibody responses...
Vaxart Appoints Edward Berg as Senior Vice President and General Counsel
14 févr. 2022 08h00 HE
|
Vaxart, Inc.
Pharmaceutical Industry Veteran Brings Broad Legal Expertise to Vaxart Senior Management Team SOUTH SAN FRANCISCO, Calif., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today...
Vaxart to Participate at the H.C. Wainwright BioConnect Virtual Conference
04 janv. 2022 08h00 HE
|
Vaxart, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Andrei Floroiu, President and Chief Executive Officer, Dr. Sean Tucker, SVP and Chief...
Vaxart to Test Cross-Reactivity of its COVID-19 Oral Tablet Vaccine Against Omicron
16 déc. 2021 08h00 HE
|
Vaxart, Inc.
Cross-reactivity will be assessed using samples from Phase II clinical participants and in a parallel animal challenge study Oral tablet’s immunogenicity profile suggests it may provide...
Vaxart Announces Acquisition of Second GMP Manufacturing Facility
01 déc. 2021 08h00 HE
|
Vaxart, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) has entered into an agreement with Kindred Bioscience, Inc. (“KindredBio”) for the purchase of KindredBio’s...
Vaxart to Present at World Vaccine & Immunotherapy Congress West Coast 2021 on November 30, 2021
23 nov. 2021 08h00 HE
|
Vaxart, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced that Dr. Sean Tucker, SVP and Chief Scientific Officer, will present at the World Vaccine...